[Minimal brain dysfunction. III. Treatment (preliminary report)].
D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000503:physiopathology; D001569:Benzodiazepines; D002220:Carbamazepine / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004569:Electroencephalography; D006801:Humans; D010889:Piracetam / Q000008:administration & dosage / Q000627:therapeutic use*; D011760:Pyrrolidinones / Q000627:therapeutic use*; D012893:Sleep Wake Disorders / Q000188:drug therapy / Q000209:etiology
D014151:Anti-Anxiety Agents; D011760:Pyrrolidinones; D001569:Benzodiazepines; D002220:Carbamazepine; D010889:Piracetam
Disfunción cerebral mínima. III. Tratamiento (reporte preliminar).